SPENCER PHARMACEUTICAL INC

As of March 31, 2004, SPENCER PHARMACEUTICAL INC carries a market capitalization of 17.12M, placing it among publicly traded companies globally. Its enterprise value stands at 17.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2004, SPENCER PHARMACEUTICAL INC has 1.34M shares outstanding.

These figures are as of March 31, 2004.

As of March 31, 2004, SPENCER PHARMACEUTICAL INC trades at an EV/EBITDA multiple of 12.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. Its EV/EBIT multiple of 13.24 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 17.66M versus a market cap of 17.12M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2004, SPENCER PHARMACEUTICAL INC maintains a current ratio of 0.53, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2004. Return on assets (ROA) is negative at -42.92, reflecting losses generated across the asset base.

These figures cover the twelve months ended March 31, 2004. EBITDA reached 1.37M, while operating income came in at -1.33M.

As of March 31, 2004, SPENCER PHARMACEUTICAL INC holds 2,832.00 in cash and equivalents against 541,446.00 in total debt, resulting in a net debt position of 538,614.00. Total book value stands at 3.84M, with working capital of -829,933.00 providing operational flexibility.

SPENCER PHARMACEUTICAL INC produced -635,304.00 in operating cash flow over the twelve months ended March 31, 2004.

These figures cover the twelve months ended March 31, 2004. Free cash flow yield is negative at -5.30: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.09, meaning SPENCER PHARMACEUTICAL INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.

SPENCER PHARMACEUTICAL INC's most recent stock split took place on October 8, 2009 with a 25:1 split ratio.